These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 16251235)

  • 21. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.
    Rashidi A; Sehgal AR; Rahman M; O'Connor AS
    Am J Cardiol; 2008 Dec; 102(12):1668-73. PubMed ID: 19064021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of statin use in type 2 diabetics having macrovascular disease- at a Tertiary Care Hospital of Karachi.
    Basit A; Hydrie MZ; Hakeem R; Ahmedani MY; Masood Q
    J Ayub Med Coll Abbottabad; 2004; 16(4):60-4. PubMed ID: 15762067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
    Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
    Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction.
    Wattanakit K; Coresh J; Muntner P; Marsh J; Folsom AR
    J Am Coll Cardiol; 2006 Sep; 48(6):1183-9. PubMed ID: 16979003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype.
    Blum S; Milman U; Shapira C; Miller-Lotan R; Bennett L; Kostenko M; Landau M; Keidar S; Levy Y; Khemlin A; Radan A; Levy AP
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):e18-20. PubMed ID: 18296583
    [No Abstract]   [Full Text] [Related]  

  • 35. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study].
    de Francisco AL; De la Cruz JJ; Cases A; de la Figuera M; Egocheaga MI; Górriz JI; Llisterri JI; Marín R; Martínez Castelao A
    Nefrologia; 2007; 27(3):300-12. PubMed ID: 17725449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
    Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
    Baber U; Toto RD; de Lemos JA
    Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction.
    Lambert ND; Sacrinty MT; Ketch TR; Turner SJ; Santos RM; Daniel KR; Applegate RJ; Kutcher MA; Sane DC
    Am Heart J; 2009 Apr; 157(4):688-94. PubMed ID: 19332197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.